Literature DB >> 15959873

Twenty-six novel EFNB1 mutations in familial and sporadic craniofrontonasal syndrome (CFNS).

Ilse Wieland1, William Reardon, Sibylle Jakubiczka, Brunella Franco, Wolfram Kress, Catherine Vincent-Delorme, Patrick Thierry, Matt Edwards, Rainer König, Cristina Rusu, Susann Schweiger, Elizabeth Thompson, Sigrid Tinschert, Fiona Stewart, Peter Wieacker.   

Abstract

Craniofrontonasal syndrome (CFNS) is an X-linked disorder characterized by a more severe manifestation in heterozygous females than in hemizygous males. Heterozygous females have craniofrontonasal dysplasia (CFND) and occasionally extracranial manifestations including midline defects and skeletal abnormalities, whereas hemizygous males show no or only mild features such as hypertelorism and rarely show cleft lip or palate. Mutations in the EFNB1 gene in Xq12 are responsible for familial and sporadic CFNS. The EFNB1 gene encodes ephrin-B1, a transmembrane ligand that also exhibits receptor-like effects. We performed mutation analysis in nine unrelated families and 29 sporadic patients with CFNS. DNA sequencing revealed mutations in 33 (86.8%) cases including 26 distinct novel mutations. A recurrent nonsense mutation, c.196C>T/R66X, was detected in one family and four sporadic patients. The majority of mutations (26/33) were located in exons 2 and 3 of the EFNB1 gene encoding the extracellular ephrin domain. The mutation spectrum includes frameshift, nonsense, missense, and splice site mutations, with a predominance of frameshift and nonsense mutations resulting in premature truncation codons. For the first time we describe mutations in exons 4 and 5 of EFNB1. Of particular interest are the frameshift mutations located in the last 25 codons of EFNB1 encoding the carboxyterminal end of ephrin-B1. They result in an extension by 44 residues. These mutations disrupt the intracellular binding sites for Grb4 and PDZ-effector proteins involved in reverse signaling. We conclude that the major causes of familial as well as sporadic CFNS are loss of function mutations in the EFNB1 gene that comprise premature termination or abrogate receptor-ligand interaction, oligomerization, and ephrin-B1 reverse signaling. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15959873     DOI: 10.1002/humu.20193

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  18 in total

1.  The origin of EFNB1 mutations in craniofrontonasal syndrome: frequent somatic mosaicism and explanation of the paucity of carrier males.

Authors:  Stephen R F Twigg; Kazuya Matsumoto; Alexa M J Kidd; Anne Goriely; Indira B Taylor; Richard B Fisher; A Jeannette M Hoogeboom; Irene M J Mathijssen; M Teresa Lourenco; Jenny E V Morton; Elizabeth Sweeney; Louise C Wilson; Han G Brunner; John B Mulliken; Steven A Wall; Andrew O M Wilkie
Journal:  Am J Hum Genet       Date:  2006-04-28       Impact factor: 11.025

Review 2.  Clinical, genetic and imaging findings identify new causes for corpus callosum development syndromes.

Authors:  Timothy J Edwards; Elliott H Sherr; A James Barkovich; Linda J Richards
Journal:  Brain       Date:  2014-01-28       Impact factor: 13.501

3.  Craniofrontonasal dysplasia: hypertelorism correction in late presenting patients.

Authors:  Cassio Eduardo Raposo-Amaral; Gabriel Resende; Rafael Denadai; Enrico Ghizoni; Cesar Augusto Raposo-Amaral
Journal:  Childs Nerv Syst       Date:  2021-04-16       Impact factor: 1.475

4.  Ephrin reverse signaling controls palate fusion via a PI3 kinase-dependent mechanism.

Authors:  Symone San Miguel; Maria J Serrano; Ashneet Sachar; Mark Henkemeyer; Kathy K H Svoboda; M Douglas Benson
Journal:  Dev Dyn       Date:  2011-02       Impact factor: 3.780

5.  Phenotypes of craniofrontonasal syndrome in patients with a pathogenic mutation in EFNB1.

Authors:  M E P van den Elzen; S R F Twigg; J A C Goos; A J M Hoogeboom; A M W van den Ouweland; A O M Wilkie; I M J Mathijssen
Journal:  Eur J Hum Genet       Date:  2013-11-27       Impact factor: 4.246

6.  A Family with Craniofrontonasal Syndrome and a Mutation (p.G151S) in the EFNB1 Gene: Expanding the Phenotype.

Authors:  Jaime Toral-López; Luz M González-Huerta; Olga Messina Baas; Sergio A Cuevas-Covarrubias
Journal:  Mol Syndromol       Date:  2016-03-19

7.  Ephrin-B1 regulates axon guidance by reverse signaling through a PDZ-dependent mechanism.

Authors:  Jeffrey O Bush; Philippe Soriano
Journal:  Genes Dev       Date:  2009-06-10       Impact factor: 11.361

8.  The impact of CFNS-causing EFNB1 mutations on ephrin-B1 function.

Authors:  Roman Makarov; Bernhard Steiner; Zoran Gucev; Velibor Tasic; Peter Wieacker; Ilse Wieland
Journal:  BMC Med Genet       Date:  2010-06-17       Impact factor: 2.103

9.  Additional EFNB1 mutations in craniofrontonasal syndrome.

Authors:  Deeann Wallis; Felicitas Lacbawan; Mahim Jain; Vazken M Der Kaloustian; Carlos E Steiner; John B Moeschler; H Wolfgang Losken; Ilkka I Kaitila; Stephen Cantrell; Virginia K Proud; John C Carey; Donald W Day; Dorit Lev; Ahmad S Teebi; Luther K Robinson; H Eugene Hoyme; Nadia Al-Torki; Jacqueline Siegel-Bartelt; John B Mulliken; Nathaniel H Robin; Dolores Saavedra; Elaine H Zackai; Maximilian Muenke
Journal:  Am J Med Genet A       Date:  2008-08-01       Impact factor: 2.802

10.  Evaluation of Sporadic and Familial Cases with Craniofrontonasal Syndrome: A Wide Clinical Spectrum and Identification of a Novel EFNB1 Gene Mutation.

Authors:  Semra Gürsoy; Filiz Hazan; Tülay Öztürk; Rüya Çolak; Şebnem Çalkavur
Journal:  Mol Syndromol       Date:  2021-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.